News · 26 weeks10-100%
2025-12-142026-06-07
Mix790d
- SEC Filings5(71%)
- Dividends1(14%)
- Other1(14%)
Latest news
25 items- SECInterpace Biosciences, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
- SECSEC Form 10-Q filed by Interpace Biosciences, Inc.10-Q - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
- PRInterpace Biosciences Announces First Quarter 2026 Financial and Business ResultsQ1 Revenue of $9.0 millionQ1 Income from Continuing Operations of $0.8 millionQ1 Thyroid volume year-over-year increase of 10%Q1 Thyroid revenue year-over-year increase of 12% PARSIPPANY, NJ, May 12, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the first quarter ended March 31, 2026 and provided a business and financial update. Interpace generated Q1 2026 revenue of $9.0 million on 12% year-over-year thyroid revenue growth, delivered $0.8 million of income from continuing operations, and produced Adjusted EBITDA of $1.6 million, or 17% of revenue. "Our first quarter results demonstrate continued mo
- SECAmendment: SEC Form 10-K/A filed by Interpace Biosciences, Inc.10-K/A - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
- SECInterpace Biosciences, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
- SECSEC Form 10-K filed by Interpace Biosciences, Inc.10-K - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
- PRInterpace Biosciences Announces Fourth Quarter and Full Year 2025 Financial and Business ResultsQ4 and FY Revenue of $9.2 million and $38.7 millionQ4 and FY Income from Continuing Operations of $22.8 million and $25.0 million (benefiting from a one-time, non-cash tax-related accounting adjustment)Q4 and FY Thyroid volume year-over-year increase of 11% and 13%Q4 and FY Thyroid revenue year-over-year increase of 14% and 21% PARSIPPANY, NJ, March 30, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the fourth quarter and full year ended December 31, 2025 and provided a business and financial update. Q4 and FY revenue were $9.2 million and $38.7 million, respectively. Q4 and FY income from continuing
- INSIDERLarge owner 1315 Capital Ii, L.P. converted options into 9,405,941 shares (SEC Form 4)4 - INTERPACE BIOSCIENCES, INC. (0001054102) (Issuer)
- INSIDERLarge owner Ampersand 2018 Limited Partnership converted options into 13,861,386 shares (SEC Form 4)4 - INTERPACE BIOSCIENCES, INC. (0001054102) (Issuer)
- SECInterpace Biosciences, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
- SECInterpace Biosciences, Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
- SECInterpace Biosciences, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
- SECSEC Form 10-Q filed by Interpace Biosciences, Inc.10-Q - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
- PRInterpace Biosciences Announces Third Quarter 2025 Financial and Business Results●Q3 Revenue of $8.8 million ●Q3 Cash Collections of $10.0 million ●Q3 Thyroid test volume up 12% year-over-year to record levels ●Q3 Thyroid revenue of $8.8M; up 22% year-over-year to record levels PARSIPPANY, NJ, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the third quarter ended September 30, 2025 and provided a business and financial update. Third quarter Net Revenue was $8.8 million. Income from continuing operations in the third quarter of 2025 was $1.0 million. "The Company delivered record thyroid test volumes, revenue, and cash collections during the quarter, driven by higher te
- PRInterpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual MeetingHighlights Independent institutional experience shows archival cytology slides enabled successful molecular results in cases previously insufficient for testing by another commercially available molecular diagnostic test, helping avoid repeat FNAsLarge real-world analysis (n=28,144) demonstrates how ThyGeNEXT® + ThyraMIR®v2 refines risk in Bethesda III/IV nodules, especially in RAS-like and mutation-negative casesPresentations were held during the ATA Annual Meeting, September 10–14, 2025, at the Westin Kierland in Scottsdale, Arizona PARSIPPANY, NJ, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) presented two new scientific pos
- SECInterpace Biosciences, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
- SECSEC Form 10-Q filed by Interpace Biosciences, Inc.10-Q - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
- PRInterpace Biosciences Announces Second Quarter 2025 Financial and Business Results●Q2 Revenue of $9.2 million ●Q2 Cash Collections of $10.8 million ●Q2 Thyroid test volume up 16% year-over-year to record levels ●Q2 Thyroid revenue of $8.7M; up 25% year-over-year to record levels PARSIPPANY, NJ, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the second quarter ended June 30, 2025 and provided a business and financial update. Second quarter Net Revenue was $9.2 million. Loss from continuing operations in the second quarter of 2025 was $0.5 million. "The Company achieved record Thyroid test volume, revenue, cash collections in the second quarter of 2025 driven by increased vo
- SECSEC Form 10-Q filed by Interpace Biosciences, Inc.10-Q - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
- SECInterpace Biosciences, Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
- PRInterpace Biosciences Announces First Quarter 2025 Financial and Business Results●Q1 Revenue of $11.5 million; a 13% increase year-over-year ●Q1 Cash Collections of $11.3 million; a 10% increase year-over-year to record levels ●Q1 Thyroid test volume up 16% year-over-year to record levels ●Q1 Thyroid revenue of $8.0M; up 19% year-over-year to record levels ●Initiates Full Year 2025 Revenue Guidance of approximately $38 million PARSIPPANY, NJ, May 08, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. ("Interpace" or the "Company") (OTCQX:IDXG) today announced financial results for the first quarter ended March 31, 2025 and provided a business and financial update. First quarter Net Revenue was $11.5 million. Income from continuing operations in the first quarter
- SECInterpace Biosciences, Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits8-K - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
- SECAmendment: SEC Form 10-K/A filed by Interpace Biosciences, Inc.10-K/A - INTERPACE BIOSCIENCES, INC. (0001054102) (Filer)
- INSIDERChief Financial Officer Mccarthy Christopher converted options into 38,475 shares, increasing direct ownership by 463% to 46,791 units (SEC Form 4)4 - INTERPACE BIOSCIENCES, INC. (0001054102) (Issuer)
- PREffective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer RiskInterpace Expects to Remain Profitable as a Thyroid-focused Business PARSIPPANY, NJ, April 24, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, ("Interpace" or the "Company") (OTCQX:IDXG) today announced that the Genetic Testing for Oncology (L39365) Local Coverage Determination (LCD) issued by the Medicare Administrative Contractor Novitas Solutions will go into effect, ending reimbursement for their PancraGEN® test. The Centers for Medicare & Medicaid Services (CMS) delayed implementation by 60 days earlier in the year and confirmed finalization of the LCD as of today, April 24, 2025. PancraGEN is a DNA-based diagnostic molecular test. It uniquel
IDXG FAQ
7 questionsWhat does Interpace Biosciences, Inc. do?
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that...Where does IDXG stock trade?
Interpace Biosciences, Inc. (IDXG) is listed on NASDAQ.What sector and industry is IDXG in?
Interpace Biosciences, Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Interpace Biosciences, Inc. go public?
Interpace Biosciences, Inc. (IDXG) completed its IPO in n/a.What are analysts saying about IDXG?
Interpace Biosciences, Inc. has had 1 recent analyst action on file. The most recent action was from HC Wainwright & Co.: Neutral on 2021-11-17.What companies are similar to IDXG?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare IDXG side-by-side with any of them on Quantisnow.How can I track IDXG on Quantisnow?
Quantisnow aggregates Interpace Biosciences, Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IDXG to receive live email and push alerts on every new disclosure.